NEWSROOM

NRXP

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.  The ThinkEquity Conference gathers institutional investors, corporate...

read more
NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850